Abstract. Many microRNAs (miRs) have been demonstrated to play promoting or tumor suppressive roles in human cancers including breast cancer. However, the molecular mechanism of miR-133a underlying the malignant progression of breast cancer still remains obscure. In the present study we observed that the expression of miR-133a was significantly downregulated in breast cancer tissues and cell lines, when compared with adjacent non-tumor tissues and normal breast cell line, respectively. Reduced miR-133a levels were significantly associated with advanced clinical stage, lymph node metastasis, as well as shorter survival time of patients with breast cancer. Restoration of miR-133a expression led to significant decrease in the proliferation, migration, and invasion of SK-BR-3 and MDA-MB-231 cells in vitro, as well as in tumor xenograft growth in nude mice. Luciferase reporter gene assay data identified LASP1 as a target gene of miR-133a, and the expression of LASP1 was negatively regulated by miR-133a in breast cancer cells. LASP1 was significantly upregulated in breast cancer tissues and cell lines, and its upregulation was significantly associated with disease progression. siRNA-induced LASP1 downregulation caused a significant reduction in breast cancer cell proliferation, migration and invasion. Furthermore, overexpression of LASP1 impaired the suppressive effects of miR-133a upregulation on the proliferation, migration and invasion of SK-BR-3 and MDA-MB-231 cells. In summary, the present study demonstrates that miR-133a acts as a tumor suppressor in breast cancer partly at least via targeting LASP1, and thus suggests that the miR-133a/LASP1 axis may become a potential therapeutic target for breast cancer.
Introduction
Breast cancer is the most common malignant tumour and the leading cause of cancer mortality in women, resulting in 14% of cancer-related deaths (1, 2) . Although great improvements have been made in the diagnosis and treatment of breast cancer, the prognosis of patients with advanced breast cancer is still not satisfactory. In recent decades, many oncogenes and tumour suppressors have been found to play key roles in the malignant progression of breast cancer, and an understanding of the molecular mechanisms underlying breast cancer progression seems to be beneficial for the development of novel therapeutic strategies for this disease (3, 4) .
MicroRNAs (miRs), a type of non-coding RNA that are 18-25 nucleotides in length, have been demonstrated to function as gene expression regulators by directly binding to the 3'-untranslated regions (UTR) of their target mRNAs, which ultimately leads to mRNA degradation or translation inhibition (5, 6) . In the most recent decade, various miRs have been implicated in a variety of physiological and pathological processes, such as cell development and differentiation, angiogenesis and cell motility, as well as tumourigenesis (7, 8) . Moreover, many miRs, including miR-133a, have been observed to be significantly dysregulated in breast cancer and play suppressive or oncogenic roles (9) (10) (11) .
Recently, miR-133a has been suggested to play an important role in some common human cancers (12, 13) . For instance, Zheng et al (13) showed that miR-133a could inhibit colorectal cancer cell invasion through inhibition of the protein expression of Fascin1. Moreover, the suppressive role of miR-133a in breast cancer has been suggested in several recent studies (11, 14, 15) . For instance, Wu et al (14) examined miR-133a expression in formalin-fixed paraffin-embedded breast specimens from 26 benign, 34 pericancerous normal and 90 cancerous tissues using in situ hybridization and found that miR-133a was gradually downregulated from normal to benign to cancerous breast tissues. They further showed that downregulation of miR-133a was associated with disease progression and poor prognosis in breast cancer patients (14) . Moreover, Ji et al (11) showed an in vivo antitumour effect with ultrasound-mediated miRNA-133a microbubble delivery in breast cancer. In addition, the oncogenic gene FSCN1 was identified as a direct target gene of miR-133a in breast cancer (15) . However, whether other target genes of miR-133a exist in breast cancer still needs to be studied.
Growing evidence shows that LIM and SH3 domain protein 1 (LASP1) is a multi-functional protein that plays important roles in cytoskeletal formation and is a prognostic marker in different cancers (16) . LASP1 expression is correlated with the grade, size and occurrence of metastasis in clinical tumour samples (17) . LASP1 is a target of miRNAs, such as miR-203, miR-29a and miR-133b, and has been found in lung, breast cancer and hepatocarcinoma (18) (19) (20) . However, whether LASP1 is targeted by miR-133a in breast cancer remains unknown. Thus, the present study aimed to investigate the molecular mechanisms by which miR-133a mediates the malignant progression of this disease.
Materials and methods
Clinical samples. This study was approved by the Ethics Committee of Dongying People's Hospital (Dongying, China). We collected a total of 78 primary breast cancer tissues and their matched adjacent non-tumour tissues when patients underwent surgical resection at Dongying People's Hospital from April 2010 to October 2011. All the patients were female and aged 28-74 years. Of the total patients, 35.9% (28/78) presented at advanced stage (III/Iv) and 74.4% (58/78) presented with nodal metastasis (Table I) . No patient had received radiotherapy or chemotherapy prior to surgery, and informed consent was obtained. The clinical information for these patients is summarized in Table I .
Cell culture and transfection. Human normal breast cell line Hs 578Bst and human breast cancer cell lines MCF-7, MDA-MB-231, SK-BR-3, BT-20 and MDA-MB-361 were purchased from the American Type Culture Collection (ATCC; Manassas, vA, USA). All cell lines were cultured in Dulbecco's modified Eagle's medium (DMEM; Thermo Fisher Scientific, Waltham, MA, USA) supplemented with 10% fetal bovine serum (FBS; Thermo Fisher Scientific) in a 37˚C humidified atmosphere of 5% CO 2 . For the functional study of miR-133a and LASP1 in breast cancer in vitro, SK-BR-3 and MDA-MB-231 cells were transfected with scramble miR (namely, miR-NC), miR-133a mimic, negative control (NC) inhibitor, miR-133a inhibitor, NC siRNA, or LASP1 siRNA, or co-transfected with miR-133a mimic and blank pc-DNA3.1 vector (namely, miR-133a+NC) or miR-133a mimic and pc-DNA3.1-LASP1 plasmid (namely, miR-133a+LASP1) using Lipofectamine 2000 (Thermo Fisher Scientific) according to the manufacturer's instructions. For in vivo study, SK-BR-3 and MDA-MB-231 cells were stably transfected with the blank pLvTH vector or pLvTH-miR-133a lentiviral plasmid, respectively. The miR-133a inhibitor, miR-133a mimic and the negative control were purchased from Shanghai GenePharma Co., Ltd. (Shanghai, China) and the miR-133a lentiviral plasmid and blank plasmid were purchased from GeneCopoeia (Guangzhou, China). At 48 h after cell transfection, the mRNA and protein expression levels were examined.
Reverse transcription-quantitative polymerase chain reaction (RT-qPCR).
Total RNA was extracted using TRIzol reagent (Thermo Fisher Scientific), according to the manufacturer's instructions. After that, the total RNA was converted into cDNA using a Reverse Transcription kit (Thermo Fisher Scientific) according to the manufacturer's instructions. For miR or mRNA expression, real-time PCR was performed using an All-in-One miRNA qPCR kit (GeneCopoeia, Rockville, MD, USA) or a Thermo One-Step RT-PCR kit (Thermo Fisher Scientific) according to the manufacturer's instructions. U6 and GAPDH were used as internal references. The specific primer pairs used are as follows: miR-133a, forward, 5'-TGCTTTGCTAGAGCTGGTAAAATG-3' and reverse, 5'-AGCTACAGCTGGTTGAAGGG-3'; U6, forward, 5'-CTCGCTTCGGCAGCACA-3' and reverse, 5'-AACGCT TCACGAATTTGCGT-3'; LASP1, forward, 5'-TGCGGCAA GATCGTGTATCC-3' and reverse, 5'-GCAGTAGGGCTTC TTCTCGTAG-3'; GAPDH, forward, 5'-GGAGCGAGATC CCTCCAAAAT-3' and reverse, 5'-GGCTGTTGTCATACT TCTCATGG-3'. The PCR reaction conditions were 95˚C for 3 min, followed by 40 cycles of denaturation at 95˚C for 15 sec and an annealing/elongation step at 60˚C for 30 sec. The relative expression was analysed by the 2 -ΔΔCt method.
Western blot analysis. Tissues and cells were lysed in cold radioimmunoprecipitation assay buffer (Thermo Fisher Scientific), and a Bicinchoninic Acid Protein Assay kit (Thermo Fisher Scientific) was used to determine the protein concentration, according to the manufacturer's instructions. After that, 60 µg of protein was separated with 10% SDS-PAGE and was then transferred to a polyvinylidene difluoride membrane (Thermo Fisher Scientific). The membrane was then blocked in 5% non-fat milk in phosphate-buffered saline (PBS; Thermo Fisher Scientific) containing 0.1% Tween-20 (Sigma-Aldrich, St. Louis, MO, USA) at room temperature for 3 h. After being washed with PBS for 15 min, the membrane was incubated with rabbit anti-LASP1 primary antibody (1:500; Abcam, Cambridge, UK) or rabbit anti-GAPDH primary antibody (1:500; Abcam) at room temperature for 3 h. After being washed with PBS for 15 min, the membrane was incubated with goat anti-rabbit secondary antibody (1:5,000; Abcam) at room temperature for 40 min. After being washed with PBS for 15 min, the protein band was detected using an Enhanced Chemiluminescence Western Blotting kit (Thermo Fisher Scientific) and then quantified using Image Lab analysis software 3.1 (Bio-Rad Laboratories, Inc., Hercules, CA, USA), according to the manufacturer's instructions.
MTT assay. An MTT assay was used to examine cell proliferation. SK-BR-3 and MDA-MB-231 cells (5x10 3 /well) were plated into a 96-well plate and cultured at 37˚C with 5% CO 2 for 12, 24, 48 or 72 h. Subsequently, 20 µl MTT (5 mg/ml; Life Technologies/Thermo Fisher Scientific) was added. Following incubation at 37˚C for 4 h, 150 µl dimethyl sulfoxide (DMSO; Thermo Fisher Scientific) was added. Following incubation at room temperature for 10 min, formazan production was detected by determining the optical density at 570 nm using a Multiskan FC enzyme immunoassay analyser (Thermo Fisher Scientific).
Wound healing assay. SK-BR-3 and MDA-MB-231 cells were cultured in DMEM with 10% FBS to full confluence. After that, we created a wound using a plastic scraper. After being washed with PBS, cells were incubated in DMEM at 37˚C for 24 h. Then, the medium was replaced with DMEM with 10% FBS. After incubation at 37˚C for 48 h, the wound was observed under a microscope (Nikon, Tokyo, Japan).
Transwell assay. SK-BR-3 and MDA-MB-231 cell suspensions were added to the Matrigel (Chemicon, Temecula, CA, USA) pre-coated upper chamber (Chemicon), and 300 µl of DMEM with 10% FBS was added into the lower chamber. Cells were then incubated at 37˚C for 24 h. After that, those cells not through the membrane of the insert were removed using a cotton-tipped swab. Those cells on the lower surface of the membrane were stained with gentian violet (SigmaAldrich) and counted under a microscope (Olympus, Tokyo, Japan).
Tumour growth in vivo.
Male BALB/C-nu/nu nude mice (12 weeks, n=5 in each group) were maintained under pathogen-free conditions at the Animal Center of Central South University. MDA-MB-231 cells were stably transfected with the blank pLvTH vector or pLvTH-miR-133a lentiviral plasmid, which were injected subcutaneously in the dorsal flank of the mice. All mice were sacrificed under anaesthesia 60 days after cell injection. The tumour tissues were photographed and the weight was examined. The volume of tumour tissues was calculated according to: v (mm Bioinformatics prediction. The putative targets of miR-133a were predicted using TargetScan software (http://www. targetscan.org), MiRanda (http://www.microrna.org) and PicTar (pictar.mdc-berlin.de) according to the manufacturer's instructions.
Luciferase reporter gene assay. The predicted miR-133a binding sites on the 3'UTR of LASP1 (500 bp) were cloned into the pGL3 vector (Promega, Madison, WI, USA), named WT-LASP1-3'UTR. The mutant miR-133a binding sites on the 3'UTR of LASP1 were constructed using a QuikChange SiteDirected Mutagenesis kit (Stratagene; Agilent Technologies, Santa Clara, CA, USA), which was then inserted into the pGL3 vector, named Mut-LASP1-3'UTR. SK-BR-3 and MDA-MB-231 cells were co-transfected with WT-LASP1-3'UTR or Mut-LASP1-3'UTR plasmid and miR-NC or miR-133a mimic, respectively, using Lipofectamine 2000. After transfection for 48 h, the luciferase activity was examined using the Dual-Luciferase reporter assay system (Promega) according to the manufacturer's instruction.
Statistical analysis. Data in the present study was expressed as the means ± standard error. The statistical analysis was conducted using SPSS.20 software. The Student's t-test was performed for two-group comparisons, or one-way analysis of variance was performed for multiple-group comparisons. The association of gene expression with clinical characteristics was analysed using a chi-square test. A P<0.05 was considered significantly different.
Results

Downregulation of miR-133a in breast cancer.
In this study, we first determined the miR-133a levels in breast cancer tissues and matched adjacent non-tumour tissues using real-time qPCR. We found that the expression levels of miR-133a were significantly decreased in breast cancer tissues compared with adjacent non-tumour tissues (Fig. 1A) . To further confirm these findings, we examined miR-133a expression in several common breast cancer cell lines, including MCF-7, MDA-MB-231, MDA-MB-361, SK-BR-3 and BT-20. Normal human breast cell line Hs 578Bst was used as a normal control. As indicated in Fig. 1B, miR-133a was also significantly downregulated in these breast cancer cell lines compared with Hs 578Bst cells. Therefore, miR-133a is downregulated in breast cancer.
We then studied the association between miR-133a expression and clinicopathological characteristics in breast cancer. The median of miR-133a expression was used as the cut-off value. If the expression of miR-133a was greater than the median, it was defined as high expression; otherwise it was defined as low expression. As indicated in Table I , low expression of miR-133a was significantly associated with lymph node metastasis and advanced clinical stage in breast cancer. Therefore, downregulation of miR-133a is associated with the malignant progress of breast cancer.
Next, we studied the association between miR-133a expression and the prognosis of patients with breast cancer. As shown in Fig. 1C , patients with low miR-133a expression showed shorter survival time compared with those with high miR-133a expression. These findings suggest that the downregulation of miR-133a may predicate poor prognosis in breast cancer patients. Restoration of miR-133a expression inhibits breast cancer cell growth, migration and invasion. As SK-BR-3 and MDA-MB-231 cells showed the most significant reduction in miR-133a expression, we used these two cell lines in the following experiments. To restore its expression, SK-BR-3 and MDA-MB-231 cells were first transfected with miR-133a mimic. Transfection with scramble miR mimic was used as the NC group. As shown in Fig. 2A , the miR-133a levels were significantly increased in the miR-133a group compared with the NC group.
MTT, wound healing and Transwell assays were then conducted to examine cell proliferation, migration and invasion in vitro. As shown in Fig. 2 , the proliferative, migratory and invasive capacities of SK-BR-3 and MDA-MB-231 cells were significantly downregulated in the miR-133a group compared with the NC group. These findings demonstrate that miR-133a has suppressive effects on the malignant phenotypes of breast cancer cells.
After that, MDA-MB-231 cells stably transfected with miR-133a or miR-NC lentiviral plasmid were then subcutaneously implanted into nude mice. The animals were sacrificed 60 days after implantation. As indicated in Fig. 3 , overexpression of miR-133a significantly inhibited the growth of SK-BR-3 and MDA-MB-231 cells in vivo.
LASP1 is a target gene of miR-133a in breast cancer cells.
As miRs function through regulating the expression of their target genes, we then studied the potential targets of miR-133a in breast cancer cells. As shown in Fig. 4A , LASP1 was predicted to be a target gene of miR-133a. To confirm this prediction, we generated WT-LASP1-3'UTR and Mut-LASP1-3'UTR luciferase reporter plasmids (Fig. 4A) . A luciferase reporter gene assay was conducted in SK-BR-3 and MDA-MB-231 cells. As shown in Fig. 4B and C, luciferase activity was significantly reduced in SK-BR-3 and MDA-MB-231 cells co-transfected with miR-133a mimic and WT-LASP1-3'UTR plasmid, but unchanged in cells co-transfected with miR-133a mimic and Mut-LASP1-3'UTR plasmid. These data indicate that miR-133a can directly bind to the 3'UTR of LASP1 mRNA in breast cancer cells.
As miRs generally regulate negatively the expression of their target genes, we then investigated the effects of miR-133a on LASP1 expression in breast cancer cells. We found that the mRNA and protein expression of LASP1 was significantly downregulated in SK-BR-3 and MDA-MB-231 cells transfected with miR-133a mimic when compared to that in cells transfected with miR-NC ( Fig. 5A and B) . Next, SK-BR-3 and MDA-MB-231 cells were transfected with NC inhibitor or miR-133a inhibitor. After transfection, the miR-133a levels were significantly downregulated in the miR-133a inhibitor group compared to the NC inhibitor group (Fig. 5C ). We then found that the mRNA and protein expression of LASP1 were significantly increased in the miR-133a inhibitor group compared with the NC inhibitor group (Fig. 5D and E) . Accordingly, the expression of LASP1 is negatively mediated by miR-133a in breast cancer cells.
LASP1 is upregulated in breast cancer. The expression of LASP1 was then examined in breast cancer. As shown in Fig. 6A , the mRNA expression of LASP1 was significantly increased in breast cancer tissues compared with adjacent nontumour tissues. Similarly, its expression was also increased in breast cancer cell lines compared with normal breast Hs 578Bst cells (Fig. 6B and C) . We suggest that the downregulation of miR-133a may contribute to the upregulation of LASP1. After that, we studied the clinical significance of LASP1 expression in breast cancer. As shown in Table II , high expression of LASP1 was significantly associated with lymph node metastasis and advanced clinical stage in breast cancer, suggesting that the upregulation of LASP1 may contribute to malignant progression in breast cancer.
Knockdown of LASP1 inhibits the proliferation, migration and invasion of breast cancer cells.
To further clarify the potential role of LASP1 in breast cancer, SK-BR-3 and MDA-MB-231 cells were transfected with NC siRNA or LASP1 siRNA. As shown in Fig. 7A , the protein expression of LASP1 was significantly reduced after transfection with LASP1 siRNA when compared to transfection with NC siRNA. MTT, wound healing and Transwell assay data further showed that the proliferative, migratory and invasive capacities of SK-BR-3 and MDA-MB-231 cells were significantly reduced in the LASP1 siRNA group, when compared with those of the cells in the NC siRNA group (Fig. 7B-D) . These findings suggest that LASP1 plays a tumour-promoting role in breast cancer cells.
Overexpression of LASP1 attenuates the inhibitory effects of miR-133a on breast cancer cells.
Based on the findings above, we speculated that LASP1 might act as a downstream effector in the miR-133a-mediated breast cancer cells. To determine whether this speculation was correct, miR-133a-overexpressing breast cancer cells were transfected with blank pcDNA3.1 vector or pcDNA3.1-LASP1 expression plasmid. After transfection, LASP1 was significantly upregulated in the miR-133a+LASP1 group compared with in the miR-133a+NC group (Fig. 8A) . We then found that the proliferative, migratory and invasive capacities of SK-BR-3 and MDA-MB-231 cells were significantly increased in the miR-133a+LASP1 group compared with the miR-133a+NC group (Fig. 8B-D) . These findings indicate that overexpression of LASP1 impaired the suppressive effects of miR-133a on the malignant phenotypes of breast cancer cells.
Discussion
The regulatory mechanism of miR-133a underlying the malignant progression of breast cancer remains largely unknown. In the present study, we observed that miR-133a was significantly downregulated in breast cancer, and low expression of miR-133a was associated with disease progression and poor prognosis in breast cancer. Overexpression of miR-133a reduced the proliferation, migration and invasion of breast cancer cells in vitro and tumour growth in vivo. LASP1 was identified as a target gene of miR-133a in breast cancer cells, and upregulation of LASP1 was significantly associated with disease progression in breast cancer. Knockdown of LASP1 also inhibited the proliferation, migration and invasion of breast cancers, and overexpression of LASP1 impaired the suppressive effects of miR-133a upregulation on the malignant phenotypes of breast cancer cells. The suppressive role of miR-133a in breast cancer is gradually revealed (11, 14) . Wu et al (14) reported that the downregulation of miR-133a was associated with poor survival of breast cancer patients and that restoration of miR-133a expression inhibited breast cancer cell growth and invasion. Cui et al (15) found that miR-133a could inhibit breast cancer cell proliferation by inducing cell cycle arrest via the regulation of the epidermal growth factor receptormediated Akt signalling pathway. In this study, we found that miR-133a was significantly downregulated in breast cancer tissues and cell lines. Moreover, low miR-133a expression was significantly associated with lymph node metastasis, advanced clinical stage and poor prognosis in breast cancer, consistent with a previous study. Based on our findings and those of others, we suggest that miR-133a downregulation contributes to the malignant progression of breast cancer. Indeed, we found that restoration of miR-133a inhibited breast cancer cell proliferation, migration and invasion in vitro as well as tumour growth in vivo. Similarly, Ji et al (11) also reported that delivery of microbubbles containing miRNA-133a could effectively inhibit breast cancer growth in vivo. Accordingly, we suggest that miR-133a may become a promising molecular candidate for breast cancer treatment. Notably, Chan et al (21) studied circulating miR signatures for breast cancer detection and found that miR-133a was significantly upregulated in the serum of breast cancer patients. Although miR-133a plays a suppressive role in breast cancer intracellularly, it is still not known whether it has antitumour effects in circulating form. Future studies could also focus on this field, as circulating miRs have only been identified over the last few years. We then studied the regulatory mechanism of miR-133a underlying breast cancer progression. Bioinformatics analysis and luciferase reporter gene assay data confirmed that LASP1 was a direct target gene of miR-133a. LASP1 is an important member of the nebulin family of actin-binding proteins (22) . It binds to the actin cytoskeleton at extensions of the cell membrane depending on cAMP and cGMP signalling (22) . Recently, the oncogenic role of LASP1 has also been reported (20, 23, 24) . For instance, LASP1 could induce TGF-beta mediated epithelial-mesenchymal transition (EMT) in colorectal cancer by regulating S100A4 expression (25) . Upregulation of LASP1 was strongly correlated with metastatic dissemination and inferior overall and progression-free survival in medulloblastoma (26) . In this study, we found that upregulation of LASP1 might contribute to disease progression and that knockdown of LASP1 significantly inhibited the proliferation, migration and invasion of breast cancer cells, suggesting that it may be used as a potential therapeutic target of this disease. Several other studies have also reported that nuclear localization and cytosolic overexpression of LASP1 correlated with advanced tumour size, lymph node metastasis, and poor prognosis in breast cancer, and silencing of LASP1 inhibited breast cancer cell proliferation and migration (27) . Moreover, Endres et al (4) found that LASP1 could induce the expression of MMP9 as well as its secretion into the extracellular matrix, which was responsible for breast cancer cell migration and invasion. As we found that miR-133a could negatively regulate the expression of oncogenic LASP1 in breast cancer cells, we speculated that LASP1 might be involved in the tumour suppressive functions of miR-133a in breast cancer. Indeed, overexpression of LASP1 impaired the suppressive effects of miR-133a on the proliferation, migration and invasion of breast cancer cells. These findings confirmed our speculation. In fact, Wang et al (28) also reported that miR-133a could inhibit tumour growth and metastasis in colorectal cancer by targeting LASP1 and inhibiting the MAPK pathway. Therefore, the miR-133a/LASP1 signalling axis may play an essential role during the malignant progression of different cancers.
Beside miR-133a, several other miRs have also been demonstrated to directly target LASP1, and through this mechanism they play tumour suppressive roles (19, 20, 23) . For instance, miR-203 inhibits cell proliferation and migration by targeting LASP1 in triple-negative breast cancer cells (19) . miR-218 inhibits gastric cancer cell proliferation, migration, and invasion and promotes cell apoptosis by targeting LASP1 (23) . miR-133b inhibits the proliferation, migration, and invasion of hepatocarcinoma cells via targeting LASP1 (20) . Therefore, the present study expands the understanding of the function of miRs/LASP1 signalling in human cancers. However, due to lack of molecular subtyping information from breast cancer patients, we cannot clarify the relationship between different subtypes of breast cancer and miR-133a-LASP1; we therefore cannot investigate the molecular mechanisms that exist in certain subtypes, which must be our next aim.
To the best of our knowledge, the present study is the first to demonstrate that miR-133a acts as a tumour suppressor in breast cancer, at least in part by directly targeting LASP1, and thus suggests that miR-133a may become a promising therapeutic candidate for the treatment of breast cancer.
